โ† All deals

Graviton BioScience Corp

BiotechnologyBiotechnologyClinical-stageROCK2 inhibitors
๐Ÿ“ New York, NY, United Statesโ€ข Founded 2023
StreetZero Signal 74
Be the first to signal interest

About Graviton BioScience Corp

Graviton Bioscience is a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2). The company is advancing the clinical development of GV101 and its pipeline of ROCK2 inhibitors to treat serious fibrotic, inflammatory, and neurologic conditions. It operates as a B2B business in the biotechnology research industry and is headquartered in New York, New York.

LATEST FUNDINGPrivate Placement
$5.0M
Announced 2026-11-16
TOTAL RAISED$64.82M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Graviton BioScience Corp.

Free plan includes 3 full deal profiles every month.

Key highlights

  • Completed financing from Enavate Sciences to advance GV101 and ROCK2 inhibitor pipeline.
  • Total funding reached $64.82M across venture and private equity rounds.
  • Focuses on treatments for fibrotic, inflammatory, and neurologic conditions with no current cures.
  • Backed by investors including Patient Square Capital portfolio company and Sanofi.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account